Research and develop innovative pharmaceutical products. Manufacture and market a diverse range of medications. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
This is an established company with proven profits.
The gap is $28.0B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 43.9× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 79% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 12 months, company executives reported 53 buys and 26 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.63 per share each year — regular cash for whoever holds the stock.
The company’s market value is 44 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 25/100.
On our five-subject report card, TAK sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TAK is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.